03.14.22 Endpoints: GreenLight licenses mRNA shingles vaccine Share: Share on Linkedin Share on Twitter Share on Facebook GreenLight Biosciences is featured in Endpoints News following an agreement with the Serum Institute to design a messenger RNA shingles vaccine and two other messenger RNA products. “GreenLight’s approach resonates with our mission to make healthcare equitable for all,” SII CEO Adar Poonawalla said in a statement. “Messenger RNA technology will play a key role in reducing the burden of human suffering caused by vaccine-preventable diseases across LMICs.”There is an option to expand the license to two additional vaccines or therapies to be named later, GreenLight said in a release, and the shingles vaccine manufacturing process will be transferred to the SII facility in Pune, India. Read the full article here. Find out more about how GreenLight manufactures RNA.